Hofmann H, Holzmann H
Institut für Virologie der Universität Wien.
Wien Klin Wochenschr. 1995;107(11):336-9.
Sera from 1274 patients were tested for IgG antibodies to hepatitis E using the newly developed Abbott Enzyme immunoassay (EIA). All tested patients had previously proved to be negative for hepatitis A, B, and C. 180 suffered from hepatitis, in the remaining 1094 the hepatitis tests were done for other reasons (presurgical, pregnancy etc.). No clear-cut distinction was found between positive and negative sera in the Abbott ELISA: Therefore the cut-off value was set somewhat higher than as stated by the producer. Thus, 15 (8.3%) of the hepatitis patients and 25 (2.3%) of the remaining patients were positive. Epidemiological data were available from 12 positive patients. Seven had been in countries endemic for hepatitis E, however 5-all Austrian citizens-had never visited such an area. These data can be explained either by unspecific (false) positive tests or by endemic occurrence of hepatitis E in Austria, which, however, seems unlikely.
使用新开发的雅培酶免疫测定法（EIA）对1274例患者的血清进行了戊型肝炎IgG抗体检测。所有接受检测的患者此前均被证明甲型、乙型和丙型肝炎检测呈阴性。180例患有肝炎，其余1094例因其他原因（术前、妊娠等）进行了肝炎检测。在雅培酶联免疫吸附测定中，阳性和阴性血清之间未发现明确的区别：因此，临界值设定得比生产商规定的略高。因此，15例（8.3%）肝炎患者和25例（2.3%）其余患者呈阳性。有12例阳性患者的流行病学数据。7例曾去过戊型肝炎流行国家，然而，5例——均为奥地利公民——从未去过此类地区。这些数据可以用非特异性（假）阳性检测来解释，也可以用奥地利戊型肝炎的地方性发生来解释，然而，这似乎不太可能。
